The rationale for the use of AChE inhibitors is to stop the breakdown of synaptic acetylcholine, amplify and extend its impact in the basal forebrain cholinergic system, and to enhance the cholinergic and cognitive functions which deteriorate in normal aging and AD [19,20,21,22,23,70,71,72,73]. The gene discussed is ACHE; the disease is Alzheimer disease.